An experimental once-daily pill appears to be effective at aiding weight loss and lowering blood sugar among people with type ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Luxembourg-based steelmaker ArcelorMittal is bringing on lobbying firepower as the steel conglomerate seeks to defend its ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Owned by Vietnam’s wealthiest man, VinFast is more immune to not making a profit. On Thursday, the company reported it lost ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...